

Supplementary data

Figure S1. Alignment of passage 31 wt, DS and DW IFV B/Maryland/1/59 HA sequences.

B/Maryland/1/59 HA amino acid alignment: parental strain and passage 31 wt, DS, and DW

S136T in DS and DW

G137R in DS and DW

V155I in DS

```
DS      ----YLLMVVTSNADRICTGITSSNSPHVVKATATQGEVNVTVGVIPLTPTTKSHFANLKG 56
DW      -XLIVLLMVVTSNADRICTGITSSNSPHVVKATATQGEVNVTVGVIPLTPTTKSHFANLKG 56
WT      XXIIIVLLMVVTSNADRICTGITSSNSPHVVKATATQGEVNVTVGVIPLTPTTKSHFANLKG 56
Parental -----XVTSNADRICTGITSSNSPHVVKATATQGEVNVTVGVIPLTPTTKSHFANLKG 56
          *****

DS      TQTRGKLCPNCLNCTDLVALGRPKCMGTIPSAKVSILHEVKPVTSGCFPIMHDRTKIRQ 110
DW      TQTRGKLCPNCLNCTDLVALGRPKCMGTIPSAKVSILHEVKPVTSGCFPIMHDRTKIRQ 110
WT      TQTRGKLCPNCLNCTDLVALGRPKCMGTIPSAKVSILHEVKPVTSGCFPIMHDRTKIRQ 110
Parental TQTRGKLCPNCLNCTDLVALGRPKCMGTIPSAKVSILHEVKPVTSGCFPIMHDRTKIRQ 110
          *****

DS      LPNLLRGYENIRLSTRNVINAETAPGGPYTVGTRSCPNVTVNGKGFETMAWAIPKKNK 159
DW      LPNLLRGYENIRLSTRNVINAETAPGGPYTVGTRSCPNVTVNGKGFETMAWAIPKKNK 159
WT      LPNLLRGYENIRLSTRNVINAETAPGGPYTVGTRSCPNVTVNGKGFETMAWAIPKKNK 159
Parental LPNLLRGYENIRLSTRNVINAETAPGGPYTVGTRSCPNVTVNGKGFETMAWAIPKKNK 159
          *****

DS      TATNPLIVEVPYICTKGEDQITVWGFHSDDETQMVILYGDSKPKQFTSSANGVITHYVSQ 216
DW      TATNPLIVEVPYICTKGEDQITVWGFHSDDETQMVILYGDSKPKQFTSSANGVITHYVSQ 216
WT      TATNPLIVEVPYICTKGEDQITVWGFHSDDETQMVILYGDSKPKQFTSSANGVITHYVSQ 216
Parental TATNPLIVEVPYICTKGEDQITVWGFHSDDETQMVILYGDSKPKQFTSSANGVITHYVSQ 216
          *****

DS      IGGFPNQTETEGLKQSGRIVVDYIVQKPGKGTGTIVYQRGVLLPQKVVWCASGRSKVIKGS 272
DW      IGGFPNQTETEGLKQSGRIVVDYIVQKPGKGTGTIVYQRGVLLPQKVVWCASGRSKVIKGS 272
WT      IGGFPNQTETEGLKQSGRIVVDYIVQKPGKGTGTIVYQRGVLLPQKVVWCASGRSKVIKGS 272
Parental IGGFPNQTETEGLKQSGRIVVDYIVQKPGKGTGTIVYQRGVLLPQKVVWCASGRSKVIKGS 272
          *****

DS      PLIGEADCLHEKYGGLNKSHPYTTGEHAKAIGNCPIWVKTPKLANGTKYRPPAKLLKER 329
DW      PLIGEADCLHEKYGGLNKSHPYTTGEHAKAIGNCPIWVKTPKLANGTKYRPPAKLLKER 329
WT      PLIGEADCLHEKYGGLNKSHPYTTGEHAKAIGNCPIWVKTPKLANGTKYRPPAKLLKER 329
Parental PLIGEADCLHEKYGGLNKSHPYTTGEHAKAIGNCPIWVKTPKLANGTKYRPPAKLLKER 329
          *****

DS      GFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEV 389
DW      GFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEV 389
WT      GFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEV 389
Parental GFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEV 389
          *****

DS      KNLQRLSGAMDELHNEILELDEKVDLDRADTISSQIELAVLLSNEGIINSEDEHLLALER 449
DW      KNLQRLSGAMDELHNEILELDEKVDLDRADTISSQIELAVLLSNEGIINSEDEHLLALER 449
WT      KNLQRLSGAMDELHNEILELDEKVDLDRADTISSQIELAVLLSNEGIINSEDEHLLALER 449
Parental KNLQRLSGAMDELHNEILELDEKVDLDRADTISSQIELAVLLSNEGIINSEDEHLLALER 449
          *****

DS      KLKKMLGPSAIDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNIITAASLNDD 509
DW      KLKKMLGPSAIDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNIITAASLNDD 509
WT      KLKKMLGPSAIDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNIITAASLNDD 509
Parental KLKKMLGPSAIDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNIITAASLNDD 509
          *****

DS      GLDNHTILLYYSTAASSLAVILMIAIFIVYMVSRDNVSCSICL 550
DW      GLDNHTILLYYSTAASSLAVILMIAIFIVYMVSRDNVSCSICL 550
WT      GLDNHTILLYYSTAASSLAVILMIAIFIVYMVSRDNVSCSICL 550
Parental GLDNHTILLYYSTAASSLAVILMIAIFIVYMVSRDNVSCSICL 550
          *****
```

Figure S2. Alignment of passage 31 wt, DS and DW IFV B/Maryland/1/59 NA sequences.

**B/Maryland/1/59 NA amino acid alignment:
parental strain and passage 31 wt, DS, and DW**

```

S386G in wt
D387G in wt
M467V in wt
L38P in DS
A268I in DW
W438L in DS and DW

DS      -----VLLSLYVSASLSYLLYSDIILKFSPTKITAPTMSLECVNVSNAQAVN 63
DW      -----VLLSLYVSASLSYLLYSDIILKFSPTKITAPTMSLECVNVSNAQAVN 63
Parental TIQTLTLFLTSGGVLLSLYVSASLSYLLYSDIILKFSPTKITAPTMSLECVNVSNAQAVN 63
WT      TIQTLTLFLTSGGVLLSLYVSASLSYLLYSDIILKFSPTKITAPTMSLECVNVSNAQAVN 63
*****

DS      HSATKEMTFLLPEPEWYPRLSCQGSTFQKALLISPHRFGETRGNAPLIIREPFVACGP 126
DW      HSATKEMTFLLPEPEWYPRLSCQGSTFQKALLISPHRFGETRGNAPLIIREPFVACGP 126
Parental HSATKEMTFLLPEPEWYPRLSCQGSTFQKALLISPHRFGETRGNAPLIIREPFVACGP 126
WT      HSATKEMTFLLPEPEWYPRLSCQGSTFQKALLISPHRFGETRGNAPLIIREPFVACGP 126
*****

DS      KECRFHALTHYAAQPGGYNGTRKDRNKLRLHLSVKLGKIPTVENSIFHMAAWSGSACHD 185
DW      KECRFHALTHYAAQPGGYNGTRKDRNKLRLHLSVKLGKIPTVENSIFHMAAWSGSACHD 185
Parental KECRFHALTHYAAQPGGYNGTRKDRNKLRLHLSVKLGKIPTVENSIFHMAAWSGSACHD 185
WT      KECRFHALTHYAAQPGGYNGTRKDRNKLRLHLSVKLGKIPTVENSIFHMAAWSGSACHD 185
*****

DS      GREWTYIGVDGPDSDALIKIKYGEAYTDYHSYAHNLRQTQESACNCIGGDCYLMITDGS 245
DW      GREWTYIGVDGPDSDALIKIKYGEAYTDYHSYAHNLRQTQESACNCIGGDCYLMITDGS 245
Parental GREWTYIGVDGPDSDALIKIKYGEAYTDYHSYAHNLRQTQESACNCIGGDCYLMITDGS 245
WT      GREWTYIGVDGPDSDALIKIKYGEAYTDYHSYAHNLRQTQESACNCIGGDCYLMITDGS 245
*****

DS      ASGISKCRFLKIREGRIIKEIFPAGRVEHTEECTCGFASNKTIECACRDNSYAKRPFVK 304
DW      ASGISKCRFLKIREGRIIKEIFPAGRVEHTEECTCGFASNKTIECACRDNSYAKRPFVK 304
Parental ASGISKCRFLKIREGRIIKEIFPAGRVEHTEECTCGFASNKTIECACRDNSYAKRPFVK 304
WT      ASGISKCRFLKIREGRIIKEIFPAGRVEHTEECTCGFASNKTIECACRDNSYAKRPFVK 304
*****

DS      LNVETDAEIRLMCTETYLDTPRPDDGSITGPCESNGDKLGGIKGGFVHQRMASKIGRW 361
DW      LNVETDAEIRLMCTETYLDTPRPDDGSITGPCESNGDKLGGIKGGFVHQRMASKIGRW 361
Parental LNVETDAEIRLMCTETYLDTPRPDDGSITGPCESNGDKLGGIKGGFVHQRMASKIGRW 361
WT      LNVETDAEIRLMCTETYLDTPRPDDGSITGPCESNGDKLGGIKGGFVHQRMASKIGRW 361
*****

DS      YSRTMSKTERMGMELYVKYDGDPTDSDALAPSGVMVSMKEPGWYSFGFEIKDKKCDVPC 421
DW      YSRTMSKTERMGMELYVKYDGDPTDSDALAPSGVMVSMKEPGWYSFGFEIKDKKCDVPC 421
Parental YSRTMSKTERMGMELYVKYDGDPTDSDALAPSGVMVSMKEPGWYSFGFEIKDKKCDVPC 421
WT      YSRTMSKTERMGMELYVKYDGDPTDSDALAPSGVMVSMKEPGWYSFGFEIKDKKCDVPC 421
*****

DS      IGIEMVHDGGKETLHSAATAIYCLMGSGQLLWDIVTGVDMAL 469
DW      IGIEMVHDGGKETLHSAATAIYCLMGSGQLLWDIVTGVDMAL 469
Parental IGIEMVHDGGKETLHSAATAIYCLMGSGQLLWDIVTGVDMAL 469
WT      IGIEMVHDGGKETLHSAATAIYCLMGSGQLLWDIVTGVDMAL 469
*****

```


Figure S3. Alignment of passage 26 wt, DS and DW IFV A/Victoria/3/75 HA sequences.

A/Victoria/3/75 HA amino acid alignment: parental strain and passage 26 wt, DS, and DW

T10I in wt		
S186I in DS and DW		
N248S in DW		
DS	XXTIIALSIFCLVFAQDLPGNDNNSTATLCLGHHAVPNGTLVKTITNDQIEVTNAT	40
DW	MKTIIALSIFCLVFAQDLPGNDNNSTATLCLGHHAVPNGTLVKTITNDQIEVTNAT	40
Parental	XXTIIALSIFCLVFAQDLPGNDNNSTATLCLGHHAVPNGTLVKTITNDQIEVTNAT	40
WT	XXTIIKLSYIFCLVFAQDLPGNDNNSTATLCLGHHAVPNGTLVKTITNDQIEVTNAT	40

DS	ELVQSSSTGKICNNPHRILDGINCTLIDALLGDPHCDGFQNEKWDLFVERSKAFSNCYPY	100
DW	ELVQSSSTGKICNNPHRILDGINCTLIDALLGDPHCDGFQNEKWDLFVERSKAFSNCYPY	100
Parental	ELVQSSSTGKICNNPHRILDGINCTLIDALLGDPHCDGFQNEKWDLFVERSKAFSNCYPY	100
WT	ELVQSSSTGKICNNPHRILDGINCTLIDALLGDPHCDGFQNEKWDLFVERSKAFSNCYPY	100

DS	DVPDYASLRSLVASSGTLEFINEGFNWTGVTQNGGSNACKRGPDIGFFSRLNWLKSGST	160
DW	DVPDYASLRSLVASSGTLEFINEGFNWTGVTQNGGSNACKRGPDIGFFSRLNWLKSGST	160
Parental	DVPDYASLRSLVASSGTLEFINEGFNWTGVTQNGGSNACKRGPDIGFFSRLNWLKSGST	160
WT	DVPDYASLRSLVASSGTLEFINEGFNWTGVTQNGGSNACKRGPDIGFFSRLNWLKSGST	160

DS	YPVQNVTMPNNDNSDKLYIWGVHHPITDKEQTDLYVQASGKVTVSTKRSQQTIIIPNVGSR	220
DW	YPVQNVTMPNNDNSDKLYIWGVHHPITDKEQTDLYVQASGKVTVSTKRSQQTIIIPNVGSR	220
Parental	YPVQNVTMPNNDNSDKLYIWGVHHPITDKEQTDLYVQASGKVTVSTKRSQQTIIIPNVGSR	220
WT	YPVQNVTMPNNDNSDKLYIWGVHHPITDKEQTDLYVQASGKVTVSTKRSQQTIIIPNVGSR	220

DS	PWVRGLSSRISYWTIVKPGDILVINSNGLIAPRGYFKMRTGKSSIMRSDAPIGTCSSE	280
DW	PWVRGLSSRISYWTIVKPGDILVINSNGLIAPRGYFKMRTGKSSIMRSDAPIGTCSSE	280
Parental	PWVRGLSSRISYWTIVKPGDILVINSNGLIAPRGYFKMRTGKSSIMRSDAPIGTCSSE	280
WT	PWVRGLSSRISYWTIVKPGDILVINSNGLIAPRGYFKMRTGKSSIMRSDAPIGTCSSE	280

DS	CITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIE	340
DW	CITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIE	340
Parental	CITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIE	340
WT	CITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIE	340

DS	NGWEGMIDGWYGFRHQNSEGTQQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFS	400
DW	NGWEGMIDGWYGFRHQNSEGTQQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFS	400
Parental	NGWEGMIDGWYGFRHQNSEGTQQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFS	400
WT	NGWEGMIDGWYGFRHQNSEGTQQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFS	400

DS	EVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMKNLFEKTRRQLRENAE	460
DW	EVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMKNLFEKTRRQLRENAE	460
Parental	EVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMKNLFEKTRRQLRENAE	460
WT	EVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMKNLFEKTRRQLRENAE	460

DS	DMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISF	520
DW	DMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISF	520
Parental	DMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISF	520
WT	DMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISF	520

DS	AISCFLLCVLLGFIMWACQKGNIRCNICI	550
DW	AISCFLLCVLLGFIMWACQKGNIRCNICI	550
Parental	AISCFLLCVLLGFIMWACQKGNIRCNICI	550
WT	AISCFLLCVLLGFIMWACQKGNIRCXXXX	550

Figure S4. Alignment of passage 26 wt, DS and DW IFV A/Victoria/3/75 NA sequences.

A/Victoria/3/75 NA amino acid alignment: parental strain and passage 26 wt, DS, and DW

```
Parental  -----KIITIGSVSLTIATICFLMQIAILVTTVTLHFKQYECDSPANNQVMPCEPIIIE 59
DS        -----XXITIGSVSLTIATICFLMQIAILVTTVTLHFKQYECDSPANNQVMPCEPIIIE 59
DW        -----XXXXXXSVSLTIATICFLMQIAILVTTVTLHFKQYECDSPANNQVMPCEPIIIE 59
WT        -----XXXXXXXXXXATICFLMQIAILVTTVTLHFKQYECDSPANNQVMPCEPIIIE 59
          *****

Parental  RNITEIVYLTNNTTIEKEICPKLVEYRNWSKPQCKITGFAPFSKDNSIRLSAGGDIWVIRE 119
DS        RNITEIVYLTNNTTIEKEICPKLVEYRNWSKPQCKITGFAPFSKDNSIRLSAGGDIWVIRE 119
DW        RNITEIVYLTNNTTIEKEICPKLVEYRNWSKPQCKITGFAPFSKDNSIRLSAGGDIWVIRE 119
WT        RNITEIVYLTNNTTIEKEICPKLVEYRNWSKPQCKITGFAPFSKDNSIRLSAGGDIWVIRE 119
          *****

Parental  PYVSCDPGKCYQFALGQGTTLNKHNSNDTIHDRTPHRILLMNELGVPFHLGTRQVCIAWS 179
DS        PYVSCDPGKCYQFALGQGTTLNKHNSNDTIHDRTPHRILLMNELGVPFHLGTRQVCIAWS 179
DW        PYVSCDPGKCYQFALGQGTTLNKHNSNDTIHDRTPHRILLMNELGVPFHLGTRQVCIAWS 179
WT        PYVSCDPGKCYQFALGQGTTLNKHNSNDTIHDRTPHRILLMNELGVPFHLGTRQVCIAWS 179
          *****

Parental  SSSCHDGGKAWLHVCVTGYDKNATASFIYDGKLVDSIGSWSQNILRTQESECVCINGTCTV 239
DS        SSSCHDGGKAWLHVCVTGYDKNATASFIYDGKLVDSIGSWSQNILRTQESECVCINGTCTV 239
DW        SSSCHDGGKAWLHVCVTGYDKNATASFIYDGKLVDSIGSWSQNILRTQESECVCINGTCTV 239
WT        SSSCHDGGKAWLHVCVTGYDKNATASFIYDGKLVDSIGSWSQNILRTQESECVCINGTCTV 239
          *****

Parental  VMTDGSASGRADTKILFIEEGKIVHISPLSGSAQHVEECSCYPRYPGVRCICRDNWKGSN 299
DS        VMTDGSASGRADTKILFIEEGKIVHISPLSGSAQHVEECSCYPRYPGVRCICRDNWKGSN 299
DW        VMTDGSASGRADTKILFIEEGKIVHISPLSGSAQHVEECSCYPRYPGVRCICRDNWKGSN 299
WT        VMTDGSASGRADTKILFIEEGKIVHISPLSGSAQHVEECSCYPRYPGVRCICRDNWKGSN 299
          *****

Parental  RPVVDINVKDYSIDSSYVCSGLVGDTPRKNDRSSSSYCRPNPNEKGNHGKGVKGFDDGND 359
DS        RPVVDINVKDYSIDSSYVCSGLVGDTPRKNDRSSSSYCRPNPNEKGNHGKGVKGFDDGND 359
DW        RPVVDINVKDYSIDSSYVCSGLVGDTPRKNDRSSSSYCRPNPNEKGNHGKGVKGFDDGND 359
WT        RPVVDINVKDYSIDSSYVCSGLVGDTPRKNDRSSSSYCRPNPNEKGNHGKGVKGFDDGND 359
          *****

Parental  VWMGRTI SEDSRSGYETFVKVIGGWSTPNSKLQINRQVIVDSANRSGYSGIFSV EGGKSCIN 419
DS        VWMGRTI SEDSRSGYETFVKVIGGWSTPNSKLQINRQVIVDSANRSGYSGIFSV EGGKSCIN 419
DW        VWMGRTI SEDSRSGYETFVKVIGGWSTPNSKLQINRQVIVDSANRSGYSGIFSV EGGKSCIN 419
WT        VWMGRTI SEDSRSGYETFVKVIGGWSTPNSKLQINRQVIVDSANRSGYSGIFSV EGGKSCIN 419
          *****

Parental  RCFYVELIRGREQETRVWWTNSNSIVVFCGTSGTGTGSGWPDGADINLMPI 469
DS        RCFYVELIRGREQETRVWWTNSNSIVVFCGTSGTGTGSGWPDGADINLMPI 469
DW        RCFYVELIRGREQETRVWWTNSNSIVVFCGTSGTGTGSGWPDGAXXXXXX 469
WT        RCFYVELIRGREQETRVWWTNSNSIVVFCGTSGTGTGSGWPDGADIXXXXX 469
          *****
```


Figure S5. DS IFV in plaque assay. Confluent monolayers of MDCK cells were infected with wt and DS IFVs and overlaid with 1:1 agar/medium to create plaques. Indicated viruses were applied to each well at equivalent pfu (150 pfu/well) and DAS181 was included in the agar/medium solution. Increasing concentrations of DAS181 were used (from upper left-hand corner of each plate going clockwise: 0, 0.0015, 0.015, 0.15, 1.5 and 15 μ M).




Table S1. HA and NA mutations identified during IFV B/Maryland/1/59 passaging

Passage #	HA mutations			NA mutations		
	wt	DS	DW	wt	DS	DW
4	–	–		–	–	
5	–	G137R		–	–	
6	–	G137R		–	–	
7	–	G137R		–	–	
8	–	G137R		–	–	
12	–	G137R		–	–	
13	–	G137R, S136T		–	–	
14	–	G137R, S136T		–	–	
18	–	G137R, S136T		–	W438L	
19	–	G137R, S136T	G137R, S136T	–	W438L	W438L
22	V247M	G137R, S136T	G137R, S136T, deletions ^a	S386G ^a , D387G ^a	W438L	W438L, deletions ^a
23	V247M	G137R, S136T	G137R, S136T, deletions ^a , V155I	S386G ^a , D387G ^a	W438L	W438L, deletions ^a
27	V247M	G137R, S136T	G137R, S136T, V155I	S386G ^a , D387G ^a	W438L ^a , L38P ^a	W438L, A268T ^a
29	–	G137R, S136T	G137R, S136T, V155I	S386G ^a , D387G ^a	W438L ^a , L38P ^a	W438L, A268T
34	–	G137R, S136T	G137R, S136T, V155I	S386G ^a , D387G ^a	W438L ^a , L38P ^a	W438L, A268T

–, No mutations observed.

^aSequence heterogeneity observed for this amino acid.

HA and NA sequences from wt, DS and DW IFV B/Maryland/1/59 were compared with initial viral stock sequence at most passages.

Mutations observed at select/representative passages are shown.

B/Maryland/1/59 DW virus was initiated at passage 17 and is thus only described beyond this point.

Sequence data noted with H3 and N2 numbering schemes, as previously described.^{21,22}

Full sequence alignments are shown in Figures S1 and S2.

Table S2. HA and NA mutations identified during IFV A/Victoria/3/75 passaging

Passage #	HA mutations			NA mutations		
	wt	DS	DW	wt	DS	DW
1	–	–		–	–	
2	–	–		–	–	
3	–	–		–	–	
4	–	N126T, E325K		–	–	
5	–	N126T		–	–	
6	–	S186I		–	–	
12	–	S186I		–	–	
14	–	S186I		–	K210R	
15	–	S186I	S186I	–	–	K210R ^a
17	T10I ^a	S186I	S186I, K68R ^b	–	–	K210R ^a
19	T10I	S186I	S186I, K68R ^b , N248S ^a	–	–	K210R ^a
21	T10I	S186I	S186I, K68R ^b , N248S	–	–	–
24	T10I	S186I	S186I, N248S	–	–	–
26	T10I	S186I	S186I, N248S	–	–	–

–, No mutations observed.

^aSequence heterogeneity observed for this amino acid.

^bMutation lies in HA2 segment, all others in HA1 segment.

HA and NA sequences from wt, DS and DW IFV A/Victoria/3/75 were compared with initial viral stock sequence at most passages.

Mutations observed at select/representative passages are shown.

AVictoria/3/75 DW virus was initiated at passage 14 and is thus only described beyond this point.

Sequence data noted with H3 and N2 numbering schemes, as previously described.^{21,22}

Full sequence alignments are shown in Figures S3 and S4.

Table S3. Top 20 sialylated glycan structures bound on microarray by wt and DS IFV

B/Maryland/1/59

Glycan #	Glycan structure	RFU
B/Maryland/1/59/wt		
361	Neu5Ac α 2-6GlcNAc β 1-4GlcNAc-Sp21	30797
362	Neu5Ac α 2-6GlcNAc β 1-4GlcNAc β 1-4GlcNAc-Sp21	16440
318	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -N(LT)AVL	3385
326	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β -Sp0	2157
244	Neu5Ac α 2-6Gal β 1-4GlcNAc β -Sp8	1988
246	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β -Sp0	1836
324	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-3Gal β 1-3GlcNAc β -Sp0	1300
242	Neu5Ac α 2-6Gal β 1-4[6OSO3]GlcNAc β -Sp8	1032
198	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -Sp12	912
214	Neu5Ac α 2-3GalNAc β 1-4GlcNAc β -Sp0	901
340	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-3(Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc-Sp12	880
241	Neu5Ac α 2-6GalNAc β 1-4GlcNAc β -Sp0	839
315	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -Sp12	831
282	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-3Gal β 1-3GlcNAc β -Sp0	803
237	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β -Sp0	732
342	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-3Man β 1-4GlcNAc β 1-4GlcNAc-Sp12	689
53	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -Sp13	641
52	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -Sp12	587
371	NeuAc α 2-3Gal β 1-4GlcNAc β 1-3GalNAc-Sp14	528
243	Neu5Ac α 2-6Gal β 1-4GlcNAc β -Sp0	512
B/Maryland/1/59/DS		
315	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -Sp12	3700
214	Neu5Ac α 2-3GalNAc β 1-4GlcNAc β -Sp0	3205
237	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β -Sp0	3078
373	Neu5Ac α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3GalNAc α -Sp14	2773
371	NeuAc α 2-3Gal β 1-4GlcNAc β 1-3GalNAc-Sp14	2655
282	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-3Gal β 1-3GlcNAc β -Sp0	2553
234	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β -Sp0	2552

142	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -Sp12	2442
236	Neu5Ac α 2-3Gal β 1-4GlcNAc β -Sp8	2201
361	Neu5Ac α 2-6GlcNAc β 1-4GlcNAc-Sp21	2016
312	Neu5Ac α 2-3Gal β 1-3(Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-6)GalNAc α -Sp14	1917
231	Neu5Ac α 2-3Gal β 1-4(Fuca1-3)GlcNAc β 1-3Gal β -Sp8	1850
198	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -Sp12	1802
218	Neu5Ac α 2-3Gal β 1-3(Neu5Ac α 2-3Gal β 1-4)GlcNAc β -Sp8	1796
225	Neu5Ac α 2-3Gal β 1-3GlcNAc β -Sp8	1787
318	Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-3(Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc β -N(LT)AVL	1769
238	Neu5Ac α 2-3Gal β 1-4Glc β -Sp0	1698
235	Neu5Ac α 2-3Gal β 1-4GlcNAc β -Sp0	1695
232	Neu5Ac α 2-3Gal β 1-4(Fuca1-3)GlcNAc β 1-3Gal β 1-4GlcNAc β -Sp8	1662
224	Neu5Ac α 2-3Gal β 1-3GlcNAc β -Sp0	1634

Information for the top 20 glycans bound by wt and DS IFV B/Maryland/1/59 (from graphs shown in Figure 9) is listed as the glycan number, the shorthand chemical name/structure and the RFU observed.